Literature DB >> 2527727

Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives.

C Jung-Hoffmann1, H Kuhl.   

Abstract

The serum concentrations of ethinylestradiol (EE) during the first 4 h and 24 h after intake of an oral contraceptive containing 30 micrograms EE and 75 micrograms gestodene (EE/GSD) were compared to those after intake of a preparation containing the same EE dose and 150 micrograms desogestrel (EE/DG) in each of 11 women on days 1, 10, and 21 of their 1st, 3rd, 6th, and 12th cycles. There were great interindividual variations, but during treatment with EE/GSD the EE levels were higher and the EE peaks occurred by 30 min later than during treatment with EE/DG. The areas under the EE serum concentration-versus-time curves (AUC) between 0 and 4 h were higher by 37% (p less than 0.03) and between 0 and 24 h higher by 70% (p less than 0.002) during treatment with EE/GSD. During each treatment cycle, the EE levels rose between day 1 and 10. The serum levels of corticosteroid-binding globulin (CBG), which is known to be influenced only by the estrogenic component of the combination pill, increased significantly (p less than 0.01) during each treatment cycle. CBG was elevated on day 21 of the 6th and 12th cycle by 150 to 155% and by 120 to 130% with EE/GSD and EE/DG, respectively. The difference between the two drugs was significant (p less than 0.02). During the pill-free intervals of 7 days between the treatment cycles, the CBG levels decreased but were still elevated by 85% with EE/GSD and 50% with EE/DG at the beginning of the following cycle as compared to the control cycle. The serum levels of cortisol were also significantly more elevated (p less than 0.05) during treatment with EE/GSD as compared to EE/DG. Despite the same EE dose during treatment, the higher EE levels with EE/GSD as compared to EE/DG seem to be due to a retardation of the inactivation and elimination of EE caused by the progestogen component. The rise in the EE levels during each cycle seems to be due to a reduction in the oxidative metabolism by EE itself.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527727     DOI: 10.1016/0010-7824(89)90094-2

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Authors:  Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  Proceedings of the British Pharmacological Society, British Pharmacology Section. 18-20 April 1990, Sheffield. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 3.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

5.  Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination.

Authors:  A Balogh; G Klinger; L Henschel; A Börner; R Vollanth; W Kuhnz
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Weighted serum pools in comparison to the trapezoidal rule for estimating AUCs for ethinyl estradiol. The relationship of the variance of the determination to the interindividual variance.

Authors:  T Louton; W Kuhnz; L Dibbelt; R Knuppen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 7.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  W O Spitzer; M A Lewis; L A Heinemann; M Thorogood; K D MacRae
Journal:  BMJ       Date:  1996-01-13

9.  Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey.

Authors:  Q G Li; M Hümpel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

10.  Lansoprazole does not affect the bioavailability of oral contraceptives.

Authors:  W Fuchs; R Sennewald; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.